RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as low as $0.82. RedHill Biopharma shares last traded at $0.87, with a volume of 954,952 shares traded.
在周四的交易中,红山生物医药有限公司(纳斯达克代码:RDHL-GET评级)跌破了200日移动均线。该股的200日移动均线切入位为1.46美元,最低交易价格为0.82美元。红山生物医药的股票最新报0.87美元,总成交量为954,952股。
RedHill Biopharma Price Performance
红山生物医药的价格表现
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The company has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -0.46 and a beta of 1.86.
该公司的债务权益比为9.42,流动比率为0.98,速动比率为0.79。该公司的50日简单移动均线切入位在0.94美元,200日简单移动均线切入位在1.46美元。该股市值为4,583万美元,市盈率为-0.46,贝塔系数为1.86。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last issued its earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative return on equity of 822.29% and a negative net margin of 110.31%. The firm had revenue of $18.24 million for the quarter. During the same period in the prior year, the business earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.95 earnings per share for the current year.
红山生物医药(纳斯达克代码:Rdhl-Get Rating)最近一次发布收益报告是在6月23日(星期四)。这家生物技术公司公布了本季度每股收益(0.30美元),比普遍预期的(0.40美元)高出0.10美元。红山生物医药的净资产回报率为负822.29%,净利润率为负110.31%。该公司本季度的收入为1824万美元。去年同期,该业务实现每股收益(0.53美元)。股票研究分析师平均预测,红山生物科技有限公司本年度每股收益将为0.95美元。
Institutional Inflows and Outflows
机构资金流入和流出
About RedHill Biopharma
关于雷德希尔生物医药公司
(Get Rating)
(获取评级)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
红山生物制药有限公司是一家专业的生物制药公司,主要专注于胃肠道和传染病。该公司推广胃肠药物,包括用于治疗患有慢性非癌症疼痛的成人阿片类药物引起的便秘的Movantik;用于治疗成人幽门螺杆菌感染的Talicia;以及用于治疗成人旅行者腹泻的Aemcolo。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免费获取StockNews.com关于RedHill Biophma(RDHL)的研究报告
- 耐克股票会被超卖,但仍被高估吗?
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗?
- 皇家加勒比的宽带合作能否推动收入增长?
- 芯片设备制造商Entigis很有潜力,但它现在可以买下吗?
- DocuSign在报告收益时有重要的问题需要解决
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红山生物报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对RedHill Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。